Safety study of aflibercept eye injections in Japanese glaucoma patients
Treatments studied
Part of Eyes & vision clinical trials.
This trial checks how safe aflibercept (eye injection) is for Japanese people with neovascular glaucoma. You may be able to join if you already received aflibercept treatment under the approved Japanese instructions and have the correct diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with neovascular glaucoma (a specific type of glaucoma).
- You have already received aflibercept injections into the eye using the approved Japanese instructions.
- Your situation must match what is allowed on the approved label (no safety reasons that would block use).
- You must not have glaucoma or another eye condition that is not neovascular glaucoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial tests a new injection medicine (AIV007) placed around the eye to treat wet age-related macular degeneration (a condition that damages central vision). You may qualify if you've been treated for this condition before and responded well to previous eye injections.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This trial tests a higher dose of aflibercept (8 mg) for people whose diabetic macular edema, retinal vein occlusion, or myopic choroidal neovascularization has not improved with standard treatment. The goal is to see if this stronger dose can reduce fluid and improve vision.
This study tests a higher dose of the medicine aflibercept (brand name Eylea) in people who have already had at least three eye injections for wet age-related macular degeneration or diabetic macular edema. The goal is to see how well this stronger dose works in real-life conditions and how long its effects last.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
Hear when a new Neovascular Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.